CHADWICK MOREHART: Open Payments
NPI 1912370792 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,380 in 138 payments from 21 companies in 2025. Trend: 2023 $1,917 · 2024 $2,252 · 2025 $2,380
Food & beverage: $2,380
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $642 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $237 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $217 |
| Madrigal Pharmaceuticals | 11 | $217 |
| Janssen Biotech, Inc. | 14 | $193 |
| Lilly USA, LLC | 8 | $173 |
| GENZYME CORPORATION | 7 | $164 |
| Phathom Pharmaceuticals, Inc. | 11 | $86 |
| Ardelyx, Inc. | 4 | $77 |
| Aimmune Therapeutics, Inc. | 4 | $64 |
Products named: RINVOQ, REZDIFFRA, ENTYVIO, TREMFYA, LINZESS, DUPIXENT, OMVOH, RELISTOR.
Industry payments across TX — which companies pay providers there.
